258 related articles for article (PubMed ID: 27766392)
1. HLA-haploidentical hematopoietic stem cell transplantation with low-dose thymoglobulin GVHD prophylaxis for an adult T cell leukemia/lymphoma patient treated with pretransplant mogamulizumab.
Hirosawa M; Higashi T; Iwashige A; Yamaguchi T; Tsukada J
Ann Hematol; 2017 Feb; 96(2):327-328. PubMed ID: 27766392
[No Abstract] [Full Text] [Related]
2. Reduced-intensity haploidentical peripheral blood stem cell transplantation using low-dose thymoglobulin for aggressive adult T cell leukemia/lymphoma patients in non-complete remission.
Hirosawa M; Yamaguchi T; Tanaka A; Kominato Y; Higashi T; Morimoto H; Tsukada J
Ann Hematol; 2020 Mar; 99(3):599-607. PubMed ID: 32006150
[TBL] [Abstract][Full Text] [Related]
3. Prevention of acute graft-versus-host disease in adult T-cell leukemia-lymphoma patients who received mogamulizumab before allogeneic hematopoietic cell transplantation.
Inoue Y; Nishimura N; Murai M; Matsumoto M; Watanabe M; Yamada A; Izaki M; Nosaka K; Matsuoka M
Int J Hematol; 2022 Mar; 115(3):435-439. PubMed ID: 34705226
[TBL] [Abstract][Full Text] [Related]
4. New Strategy of Acute Graft-vs-Host Disease: Investigation of a Reduced Dose of Antithymocyte Globulin in Haploidentical Hematopoietic Stem Cell Transplantation.
Sun Y; Wei C; Cao C; Tan X; Zeng H; Luo Y; Chen L
Transplant Proc; 2019 Apr; 51(3):890-895. PubMed ID: 30979481
[TBL] [Abstract][Full Text] [Related]
5. Reduced-intensity conditioning and HLA-matched haemopoietic stem-cell transplantation in patients with chronic granulomatous disease: a prospective multicentre study.
Güngör T; Teira P; Slatter M; Stussi G; Stepensky P; Moshous D; Vermont C; Ahmad I; Shaw PJ; Telles da Cunha JM; Schlegel PG; Hough R; Fasth A; Kentouche K; Gruhn B; Fernandes JF; Lachance S; Bredius R; Resnick IB; Belohradsky BH; Gennery A; Fischer A; Gaspar HB; Schanz U; Seger R; Rentsch K; Veys P; Haddad E; Albert MH; Hassan M;
Lancet; 2014 Feb; 383(9915):436-48. PubMed ID: 24161820
[TBL] [Abstract][Full Text] [Related]
6. Unrelated stem cell transplantation after a reduced intensity conditioning regimen containing high-dose thymoglobulin leads to controllable graft-versus-host disease.
Lacerda JF; Martins C; Lourenço F; Carmo JA; Juncal C; Oliveira JJ; Lacerda JM
Biol Blood Marrow Transplant; 2007 Apr; 13(4):494-7. PubMed ID: 17382257
[No Abstract] [Full Text] [Related]
7. Mogamulizumab Treatment Prior to Allogeneic Hematopoietic Stem Cell Transplantation Induces Severe Acute Graft-versus-Host Disease.
Sugio T; Kato K; Aoki T; Ohta T; Saito N; Yoshida S; Kawano I; Henzan H; Kadowaki M; Takase K; Muta T; Miyawaki K; Yamauchi T; Shima T; Takashima S; Mori Y; Yoshimoto G; Kamezaki K; Takenaka K; Iwasaki H; Ogawa R; Ohno Y; Eto T; Kamimura T; Miyamoto T; Akashi K
Biol Blood Marrow Transplant; 2016 Sep; 22(9):1608-1614. PubMed ID: 27220263
[TBL] [Abstract][Full Text] [Related]
8. Low-dose alemtuzumab vs. standard policy for prevention of graft-versus-host disease in unrelated and related allogeneic stem cell transplantation-a matched pair analysis.
Busemann C; Neumann T; Schulze M; Klenner A; Thiele T; Greinacher A; Dölken G; Krüger WH
Ann Hematol; 2013 Jul; 92(7):945-52. PubMed ID: 23463451
[TBL] [Abstract][Full Text] [Related]
9. The Impact of a Humanized CCR4 Antibody (Mogamulizumab) on Patients with Aggressive-Type Adult T-Cell Leukemia-Lymphoma Treated with Allogeneic Hematopoietic Stem Cell Transplantation.
Kawano N; Kuriyama T; Yoshida S; Kawano S; Yamano Y; Marutsuka K; Minato S; Yamashita K; Ochiai H; Shimoda K; Ishikawa F; Kikuchi I
J Clin Exp Hematop; 2017; 56(3):135-144. PubMed ID: 28331127
[TBL] [Abstract][Full Text] [Related]
10. Myeloablative haploidentical hematopoietic stem cell transplantation using basiliximab for graft-versus-host disease prophylaxis.
Huang R; Tu S; Deng L; Kang Q; Song C; Li Y
Hematology; 2015 Jul; 20(6):313-9. PubMed ID: 25321657
[TBL] [Abstract][Full Text] [Related]
11. A comparison of Campath and Thymoglobulin as part of the conditioning before allogeneic hematopoietic stem cell transplantation.
Norlin AC; Remberger M
Eur J Haematol; 2011 Jan; 86(1):57-66. PubMed ID: 20942840
[TBL] [Abstract][Full Text] [Related]
12. Dose study of thymoglobulin during conditioning for unrelated donor allogeneic stem-cell transplantation.
Remberger M; Svahn BM; Mattsson J; Ringdén O
Transplantation; 2004 Jul; 78(1):122-7. PubMed ID: 15257050
[TBL] [Abstract][Full Text] [Related]
13. Successful prevention of acute graft-versus-host disease using low-dose antithymocyte globulin after mismatched, unrelated, hematopoietic stem cell transplantation for acute myelogenous leukemia.
Kim HJ; Min WS; Cho BS; Eom KS; Kim YJ; Min CK; Lee S; Cho SG; Jin JY; Lee JW; Kim CC
Biol Blood Marrow Transplant; 2009 Jun; 15(6):704-17. PubMed ID: 19450755
[TBL] [Abstract][Full Text] [Related]
14. Impact of graft-versus-host disease on allogeneic hematopoietic cell transplantation for adult T cell leukemia-lymphoma focusing on preconditioning regimens: nationwide retrospective study.
Ishida T; Hishizawa M; Kato K; Tanosaki R; Fukuda T; Takatsuka Y; Eto T; Miyazaki Y; Hidaka M; Uike N; Miyamoto T; Tsudo M; Sakamaki H; Morishima Y; Suzuki R; Utsunomiya A
Biol Blood Marrow Transplant; 2013 Dec; 19(12):1731-9. PubMed ID: 24090597
[TBL] [Abstract][Full Text] [Related]
15. Successful treatment of primary plasma cell leukaemia by allogeneic stem cell transplantation from haploidentical sibling.
Nonami A; Miyamoto T; Kuroiwa M; Kunisaki Y; Kamezaki K; Takenaka K; Harada N; Teshima T; Harada M; Nagafuji K
Jpn J Clin Oncol; 2007 Dec; 37(12):969-72. PubMed ID: 18055567
[TBL] [Abstract][Full Text] [Related]
16. Safety of mogamulizumab for relapsed ATL after allogeneic hematopoietic cell transplantation.
Inoue Y; Endo S; Matsuno N; Kikukawa Y; Shichijo T; Koga K; Takaki A; Iwanaga K; Nishimura N; Fuji S; Fukuda T; Nosaka K; Matsuoka M
Bone Marrow Transplant; 2019 Feb; 54(2):338-342. PubMed ID: 30116017
[No Abstract] [Full Text] [Related]
17. Calcineurin inhibitor--free graft-versus-host disease prophylaxis with post-transplantation cyclophosphamide and brief-course sirolimus following reduced-intensity peripheral blood stem cell transplantation.
Solomon SR; Sanacore M; Zhang X; Brown S; Holland K; Morris LE; Bashey A
Biol Blood Marrow Transplant; 2014 Nov; 20(11):1828-34. PubMed ID: 25064745
[TBL] [Abstract][Full Text] [Related]
18. Protective conditioning for acute graft-versus-host disease.
Lowsky R; Takahashi T; Liu YP; Dejbakhsh-Jones S; Grumet FC; Shizuru JA; Laport GG; Stockerl-Goldstein KE; Johnston LJ; Hoppe RT; Bloch DA; Blume KG; Negrin RS; Strober S
N Engl J Med; 2005 Sep; 353(13):1321-31. PubMed ID: 16192477
[TBL] [Abstract][Full Text] [Related]
19. Role of antithymocyte globulin and granulocyte-colony stimulating factor-mobilized bone marrow in allogeneic transplantation for patients with hematologic malignancies.
Chen XH; Zhang C; Zhang X; Gao L; Gao L; Kong PY; Peng XG; Qi DG; Sun AH; Zeng DF; Liu H; Gong Y; Wang QY
Biol Blood Marrow Transplant; 2009 Feb; 15(2):266-73. PubMed ID: 19167687
[TBL] [Abstract][Full Text] [Related]
20. Unmanipulated HLA 2-3 antigen-mismatched (haploidentical) stem cell transplantation using nonmyeloablative conditioning.
Ogawa H; Ikegame K; Yoshihara S; Kawakami M; Fujioka T; Masuda T; Taniguchi Y; Hasei H; Kaida K; Inoue T; Kim EH; Kawase I
Biol Blood Marrow Transplant; 2006 Oct; 12(10):1073-84. PubMed ID: 17084371
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
